about
Toscana virus NSs protein inhibits the induction of type I interferon by interacting with RIG-ISerological Survey of Toscana Virus Infections in a High-Risk Population in ItalyRapid identification of Toscana virus by nested PCR during an outbreak in the Siena area of ItalyAge-Dependent Seroprevalence of Toscana Virus in Central Italy and Correlation with the Clinical ProfileEvidence of Toscana virus variants circulating in Tuscany, Italy, during the summers of 1995 to 1997.Pseudoexfoliation syndrome-associated genetic variants affect transcription factor binding and alternative splicing of LOXL1.Diagnostic tools for Toscana virus infection.Serological and molecular detection of Toscana and other Phleboviruses in patients and sandflies in Tunisia.Prevalence of toscana and sicilian phlebovirus antibodies in classic Kaposi sarcoma case patients and control subjects in sicily.Biotechnology for virus vaccine design, production, and control.Chemo-immunotherapy of colorectal carcinoma: preclinical rationale and clinical experience.Applications of influenza virosomes as a delivery system.Seroprevalence of and risk factors for Toscana and Sicilian virus infection in a sample population of Sicily (Italy)Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients.Search for Chlamydia pneumoniae genes and their expression in atherosclerotic plaques of carotid arteries.Comparison of a new prototype immunochromatographic assay and a commercial enzyme-linked immunosorbent assay for the detection of serum antibodies against Toscana virus.In vivo study of the GC90/IRIV vaccine for immune response and autoimmunity into a novel humanised transgenic mouse.Virucidal activity of a novel non-alcoholic combination of disinfectants.Genetic association study of exfoliation syndrome identifies a protective rare variant at LOXL1 and five new susceptibility loci.Immunosuppressive monoclonal antibody to CD64 from patients with long-term stable multiple sclerosis.Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients.Cetuximab ± chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro.Diagnostic potential of Toscana virus N protein expressed in Escherichia coli.Toscana virus induces interferon although its NSs protein reveals antagonistic activity.Anti-angiogenetic effects of immune-reconstituted influenza virosomes assembled with parathyroid hormone-related protein derived peptide vaccine.Truncation of the C-terminal region of Toscana Virus NSs protein is critical for interferon-β antagonism and protein stability.Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients.Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomizedType I interferons induced by endogenous or exogenous viral infections promote metastasis and relapse of leishmaniasis.A Respiratory Syncytial Virus Vaccine Vectored by a Stable Chimeric and Replication-Deficient Sendai Virus Protects Mice without Inducing Enhanced Disease.Retrospective diagnosis of West Nile virus infection in a patient with meningoencephalitis in Tuscany, Italy.Histological description of the lymphadenopathy related to Toscana virus infection. Report of a case.Bayesian skyline plot inference of the Toscana virus epidemic: a decline in the effective number of infections over the last 30 years.Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL reT-cell engineering by a chimeric T-cell receptor with antibody-type specificity for the HIV-1 gp120.Seroprevalence of hepatitis E virus (HEV) infection in blood donors and renal transplant recipients: a retrospective study from central Italy.Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients.Fast duplex one-step RT-PCR for rapid differential diagnosis of entero- or toscana virus meningitis.Recruitment of dendritic cells and enhanced antigen-specific immune reactivity in cancer patients treated with hr-GM-CSF (Molgramostim) and hr-IL-2. results from a phase Ib clinical trial.In vitro generation of cytotoxic T lymphocytes against HLA-A2.1-restricted peptides derived from human thymidylate synthase.
P50
Q24337813-5FB17889-A877-4C86-B7A5-4AA3BEBAD74AQ27473502-88E207E2-37ED-4C96-8F38-1F84013FDAEEQ27485748-039E1564-69EE-49C7-962E-E07EDB4565F1Q27489126-D4D53670-FCA1-4502-AC88-EF416771AD6DQ33674289-9020B2C6-96C5-43AD-9A7A-EF9B694DBC41Q33759171-824B8D68-CF9E-4949-9467-3262DE8C373FQ34205536-8A09F7CA-927C-4E7B-9420-589AB050E905Q34539187-57AA8B66-4EE4-4443-BA4C-98A2A996702EQ35238159-81A04539-4B8F-4642-BDAF-588A8FBCA814Q36324614-C539D6DA-FA25-4795-9B3B-77C406648A09Q36406726-E2B719C1-A411-412E-9044-4BDE84E43219Q36609105-9A5D1834-9ADC-4492-9EFF-C62ABDB42E36Q36778879-48F95E57-E5A2-4C2E-BED7-57B48070D41DQ36821179-548996C7-D0BE-41D8-9F80-9536EB15EEB0Q37874714-6DEA4367-159B-4D76-AA2C-24250A57A610Q38457914-64B06E41-2FF0-4B2F-8A46-9AD513CE6CBEQ38601504-D65E9B61-C057-42BF-82B1-9D8C8008683DQ38832701-DEF8E294-C31D-4910-A9FC-BA609088C5C1Q38883998-12A29BC7-EAD9-42CB-A136-2F805A0B62E0Q39210960-B7481077-0999-4866-863B-4C240513B5F9Q39350470-3640B45F-738A-4ABD-A0A5-1B93AF68D84CQ39535140-282726E3-DEF9-401A-A191-1F9EBCFED440Q39556053-1D03D6BB-388E-41A9-B584-549A951B7F4DQ39652674-39C6B4AF-325C-42CF-9C95-68E3CCA72F1AQ40010427-2A2D691C-BFB6-459B-95B4-D3390E5A2B54Q40134923-389A5C43-5F95-4CCB-94AB-48B2BAD38B0CQ40153561-87FA6C1E-3C6A-41B1-814F-5C3539770E3DQ40225686-72ECED74-085D-4FF5-AB1B-73B9914F6AB6Q40229581-DBDA3697-3A3A-40EF-B984-099DA3CB8DD1Q40312271-5372040E-2D9C-4905-A9CF-8E4747B15F16Q40318482-C008B189-B52B-4E7A-AB0C-688B2CA3335CQ40342211-1ED12580-6A0D-4F97-9DCE-DEFD3F7D2D18Q40389076-7746BC14-8842-497F-931D-BCCBB21ABDE6Q40400478-4B60C7FD-20B2-4BBF-B4F2-A8B61121891EQ40501551-B3E34DAB-1C0B-4912-B7BC-5D2C8A41B240Q40511528-3CAF080E-277E-445A-ABB2-1EFBE21C9527Q40535967-46C095E1-6492-4E32-8A4B-172041327B16Q40579155-9A01D692-EE86-4094-B875-FB6DF5CC1B54Q40604178-6D88FFE8-E03D-4991-A752-8CE757B55C10Q40760569-D65D748C-F4A3-4854-9E7D-00BB00DBC48B
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
MARIA GRAZIA CUSI
@ast
MARIA GRAZIA CUSI
@en
MARIA GRAZIA CUSI
@es
MARIA GRAZIA CUSI
@nl
type
label
MARIA GRAZIA CUSI
@ast
MARIA GRAZIA CUSI
@en
MARIA GRAZIA CUSI
@es
MARIA GRAZIA CUSI
@nl
prefLabel
MARIA GRAZIA CUSI
@ast
MARIA GRAZIA CUSI
@en
MARIA GRAZIA CUSI
@es
MARIA GRAZIA CUSI
@nl
P106
P1153
55664226900
P21
P31
P496
0000-0001-8869-8164